Objectives: This study was designed to evaluate how the atrial electrophysiological and antiarrhythmic effects of azimilide compare Ž . with those of the specific rapid delayed rectifier I blocker dofetilide. Background: Azimilide, a new class III drug, was initially Kr Ž . believed to be a highly selective blocker of the slow delayed rectifier I , but recent studies suggest that azimilide potently blocks I .
Introduction

Ž .
Atrial fibrillation AF is the commonest arrhythmia requiring therapy in clinical practice, and its treatment w x remains problematic 1 . Over the past several years, there have been efforts to develop new antiarrhythmic drugs, particularly agents with novel patterns of ion channel blocking properties. One potentially interesting target is the K q channel I , whose time-dependent deactivation Ks upon repolarization may allow for channel activation to accumulate at rapid rates and to contribute to rate-depenw x dent APD reduction 2 . In 1994, Busch et 
Ž
. highly potent blocker of a cloned channel minK that in Xenopus oocytes produces a current that corresponds to w x I 3 . During initial development, azimilide was consid-w x Y-shaped incision in the right atrium 11 . No information is available in the literature regarding the effects of azimilide in experimental AF, nor about the rate-dependence of the drug's effects on atrial electrophysiological properties. We therefore designed the present study to assess the actions of azimilide in a dog model of AF that we have w used extensively to study antiarrhythmic drug actions 12-x w x 14 . We used the I blocker dofetilide 2 as a comparison Kr agent, in order to evaluate whether the actions of azimilide resemble those of dofetilide, and can therefore be attributed to I blockade, or whether azimilide has distinct Kr actions compatible with a significant contribution of I Ks blockade to its antiarrhythmic properties.
Methods
General methods
Ž
. Purpose-bred dogs Marshall Farms, North Rose, NY of either sex weighing 20 to 26 kg were anesthetized with Ž morphine 2 mgrkg im initially, followed by 0.5 mgrkg . Ž iv every 2 h and a-chloralose 120 mgrkg iv followed by y1 . w x an infusion of 29.25 mgrkg h 15 . Dogs were ventilated mechanically with room air supplemented with oxygen via an endotracheal tube at 20 to 25 min with a tidal volume obtained from a nomogram. Arterial blood gases were measured every 2 h and kept in the physiological Ž . range SaO ) 90%, pH 7.38 to 7.44 . Catheters were 2 inserted into the femoral artery for blood pressure recording and blood gas measurement, and into both femoral veins for drug administration and venous blood sampling. Catheters were kept patent with heparinized 0.9% saline solution. Body temperature was maintained at 378C to 398C with a circulating water temperature control system.
The heart was exposed via a median thoracotomy and a pericardial cradle was created. Two bipolar stainless steel, Teflon-coated electrodes were inserted into the right atrial appendage for recording and stimulation, and one was inserted into the left atrial appendage for recording. A Ž programmable stimulator Digital Cardiovascular Instru-. ments, Berkeley, CA was used to stimulate the right atrium with 4 ms, twice diastolic threshold pulses. A Ž ventricular demand pacemaker GBM 5880, Medtronic, . Minneapolis, MN was used to stimulate the ventricles at Ž . 80rmin when particularly during vagal AF the ventricular rate became excessively slow. A P23 1D transducer, Ž electrophysiological amplifiers Bloom Associates, Flying . Ž Hills, PA , and paper recorder Astromed MT-95000, . Toronto, ON, Canada were used to record six standard ECG leads, atrial electrograms, and stimulation artifacts. The vagus nerves were isolated in the neck, doubly-ligated Ž . and divided, and bipolar electrodes inserted see below in each nerve. To block changes in ß-adrenergic effects on the heart, nadolol was administered as an initial dose of 0.5 mgrkg iv, followed by 0.25 mgrkg iv every 2 h.
Atrial fibrillation model
Drug effects on AF were studied in two ways. First, we analyzed the ability of each drug to terminate sustained AF maintained during continuous vagal nerve stimulation. Ž Bipolar hook electrodes stainless steel insulated with . Teflon except for the distal 1 to 2 cm were inserted via a 21-gauge needle within and parallel to the shaft of each nerve. Bilateral bipolar stimuli were applied with a stimu-Ž . lator model DS-9F, Grass Instruments, Quincy, MA set to deliver 0.1 ms square-wave pulses of 5 V applied intensity and a stimulation frequency equal to 60% of the frequency needed to produce asystole. Under control con-Ž ditions, a short burst of rapid atrial pacing 10 Hz, four . times threshold was delivered to induce AF, that was ordinarily sustained over 30 min during vagal stimulation. In isolated cases, the vagal stimulation frequency had to be increased to produce sustained AF. In such cases, the bradycardic effect of the frequency selected was noted. The vagal stimulation frequency was adjusted under control conditions, and then readjusted after each dose of a drug to maintain the same bradycardic effect. AF was Ž . defined as a rapid ) 500 min under control conditions , irregular atrial rhythm with varying electrogram morphology.
The second type of end point analyzed was the duration of non-vagal AF. AF was induced by burst atrial pacing as described above but in the absence of vagal stimulation and the duration of AF noted. This procedure was repeated 10 times under control conditions and in the presence of drug at each dose. The mean duration of AF was taken as an indicator of the ability to sustain AF under each condition.
Measurement of electrophysiological Õariables and
Õagal response Ž . The atrial effective refractory period ERP was measured with the extrastimulus method, over a range of Ž . Ž . S1S1 basic cycle lengths BCL . A premature extrastimu-Ž . lus S2 was introduced after every 15 basic stimuli, beginning with an S1S2 coupling interval at least 50 ms longer than the estimated ERP. The S1S2 interval was decreased in 10 ms decrements until failure to capture occurred, with the longest S1S2 interval consistently failing to produce a propagated response defining the ERP.
Ž . Conduction velocity CV was determined by mapping atrial activation during 1:1 atrial pacing. Five multielectrode plaques containing a total of 112 electrodes were sewn to the epicardial surface of both atria as previously w x w x described 16,17 . Previously described methods 18 were used to create activation maps during atrial pacing. A series of at least four right atrial electrodes in the line of rapid propagation from the stimulation site were identified, and conduction velocity determined by linear regression of distance from the stimulation site against local activation time. The same electrode sites were used for conduction velocity measurements under all conditions, after ascertaining that the activation pattern was constant. Both ERP and CV were measured after at least 1 min of stimulation at a given BCL to ensure steady-state effects. AF cycle length Ž . AFCL during vagal AF was determined as previously w x described 13 by determining the mean cycle length over a 1-s interval at each of the 112 recording sites, and then averaging to obtain an overall mean AFCL for each experimental condition.
The vagal nerve frequency-heart rate relation was determined under control conditions and in the presence of each dose of each drug. The vagal nerves were stimulated at a constant voltage and at frequencies ranging from 1 to 7 Hz. Stimulation at each vagal frequency was maintained for 30 s, with the heart rate assessed over the last 10 s of stimulation. A 30-s rest period was allowed after stimulation at each frequency, and we required that the sinus rate return to control values before stimulation at the next frequency.
Experimental protocols
The experimental groups studied are summarized in Ž Table 1 . Each dog received only one drug azimilide or . dofetilide at doses indicated in Table 1 . The first series of experiments were initial-dose ranging studies for AF termination. All drugs were administered intravenously via an infusion pump, with drug solutions prepared freshly on the day of the experiment and protected from light. Vagal stimulation parameters were defined under control conditions as described above, and maintenance of AF during 30 min of vagal stimulation under control conditions was verified. After a 10-min rest period, vagal stimulation was reinstituted and AF induced. Five minutes later, either Ž azimilide a series of doses of 4.5 followed by 9 mgrkg, . Ž four dogs or dofetilide sequential 0.06 mgrkg doses, two . Ž . dogs was administered Group 1A . Azimilide was never effective without at least one dose of 9 mgrkg, and dofetilide doses of 0.06 mgrkg failed to terminate AF. Based on these initial experiments, a modified loading dose regimen was developed and tested in seven dogs Ž . Group 1B . These dogs received an initial dose of 10 mgrkg of azimilide or 0.08 mgrkg of dofetilide, followed by a subsequent dose of 20 mgrkg of azimilide or 0.16 mgrkg of dofetilide if the first dose failed to terminate AF. The time course of effects on ERP and of blood levels Ž . in the case of azimilide was noted. Based on the latter observations, we concluded that dofetilide effects were well-maintained without a maintenance infusion, but that a maintenance infusion of half the loading dose per h would be needed to maintain stable azimilide concentrations and effects over time. Ž In the next series of experiments, six dogs three for . each drug received the doses developed on the basis of preliminary studies in order to ensure stable effects over Ž . time Group 2 . The doses selected for dofetilide were loading doses of 0.08 and 0.16 mgrkg of dofetilide administered at 16 mgrkg min y1 . The loading doses of azimilide were 10 mgrkg and 20 mgrkg, administered at 2 mgrkg min y1 , and were followed by maintenance infusions of 5 mgrkg and 10 mgrkg h y1 respectively. Groups 1A, 1B and 2 were used to define dose regimens with significant efficacy and stable actions over time. The final and definitive series of studies assessed the effects of these dose regimens on AF and atrial electro-Ž . physiology in seven dogs for each drug Group 3 . Under control conditions, ERP, CV, and AF duration were assessed in the absence and presence of vagal stimulation, and the maintenance of AF during 30 min of vagal stimulation was confirmed. An 8-s window of activation data was obtained during AF. AF was terminated by stopping vagal stimulation, and 10 min later AF was induced once again. After AF had been maintained for 5 min, the first dose of a drug was infused. If AF terminated within 15 min, the measurements obtained under control conditions were repeated. Since sustained AF could not be induced in the presence of drugs at doses that terminated AF, the experiment was then terminated. If AF was not stopped by the first drug dose, vagal stimulation was discontinued to allow a return to sinus rhythm. The electrophysiologic measurements were repeated, and sustained AF was once 1 . Heart rate at various vagal stimulation frequencies under control Ž . Ž . Ž . conditions and after low-A1 and high-A2 dose azimilide left , and Ž . Ž . under control conditions and after low-D1 and high-D2 dose dofetilide. Neither drug altered heart rate significantly at any frequency of vagal stimulation, although both tended to slow basal heart rate. more induced in the presence of vagal stimulation. After 5 min of AF, the second dose of the same drug was infused. Electrophysiologic measurements were then repeated, following either drug-induced conversion to sinus rhythm or, if the latter did not occur within 15 min of the end of the loading dose, following the cessation of vagal stimulation to allow for restoration of sinus rhythm. An 8-s window of activation data during AF was obtained at the time of AF Ž conversion with a pre-trigger used to assure at least 4 s of . data during AF prior to conversion . If AF was not converted to sinus rhythm, an 8-s window of data during AF was obtained immediately prior to stopping vagal stimulation.
Electrophysiologic measurements and vagal frequencyresponse curves were obtained in 7 Group 3 dogs for each Ž . Fig. 2 . Left. Efficacy in terminating vagal AF, for low-A1 and high-Ž .
Ž . Ž . A2 dose of azimilide in 14 dogs, and for low-D1 and high-D2 dose dofetilide in 12 dogs. ) P -0.05 vs. corresponding dose of azimilide. Ž . Ž. Right. Duration of AF mean"SEM under control conditions C , and Ž . Ž . Ž . after low-A1 and high-A2 dose azimilide or low-D1 and high-Ž .
Ž . D2 dose dofetilide ns 7 dogs for each drug . AF duration was determined by inducing AF 10 times under each condition and using average value for each condition in each dog. ) ) P -0.01; ) ) ) P -0.001 for duration in presence of drug versus control value. . control , but no significant ERP changes occurred over time after drug infusion. Results are mean"SEM in three dogs. Right. Changes in ERP Ž . after dose 1 and dose 2 of azimilide mean"SEM in three dogs . Once Ž again, changes were highly significant vs. control P -0.001 for each . dose , but ERP did not change significantly during 60 min of drug infusion.
drug. Drug efficacy in AF termination was analyzed for all dogs receiving the definitive loading doses. For azimilide, this included 7 Group 3 dogs, 3 Group 2 dogs and 4 Group 1B dogs. One azimilide dog in Group 1B died for unknown reasons several minutes after receiving the second loading dose and was not included in the efficacy analysis. For dofetilide, the efficacy analysis was based on 12 dogs: 7 from Group 3, 3 from Group 2 and 2 from Group 1B.
Statistical analysis
Group data are represented as the mean "SE. Statistical analysis was by analysis of variance for repeated measures and a chi-square test for contingency comparisons. Two-tailed tests were used, and a P -0.05 was taken to indicate statistical significance. 86"3 -8 4 "6 -9 1 "4 9 8 "5 8 9 "7 9 8 "7 250 87"2 8 7 "3 8 5 "3 8 3 "4 9 2 "4 9 8 "5 9 0 "7 9 9 "6 300 88"4 9 2 "4 8 7 "6 9 1 "4 9 4 "4 101"5 9 2 "6 9 8 "7 400 89"3 9 4 "4 8 8 "5 9 1 "4 9 3 "4 100"4 9 1 "7 9 9 "6
Results
Both azimilide and dofetilide slowed spontaneous rate, but neither drug significantly altered the bradycardic effect Ž of vagal nerve stimulation as studied in Group 3 dogs Fig. . 1 . In analyzing dogs for AF conversion, we used all dogs that received the definitive loading dose regimen for either Ž drug 14 for azimilide, 12 for dofetilide as described in . section 2.4 above . The lower doses of azimilide and dofetilide had comparable efficacy in converting vagal AF Ž . to sinus rhythm Fig. 2, left . On the other hand, the higher dose of azimilide resulted in substantially greater effective-Ž . ness in converting AF cumulative efficacy of 93% com-Ž . pared to the higher dose of dofetilide 50% . When only Ž . Group 3 dogs n s 7 per group are considered, the same Ž pattern of efficacy is observed 43% each for low-dose azimilide and dofetilide; 100% for high-dose azimilide vs.
. 43% for high-dose dofetilide . Azimilide and dofetilide were very effective in reducing the duration of non-sustained AF occurring in the absence of vagal stimulation Ž . Fig. 2 , right .
Both azimilide and dofetilide increased ERP signifi-Ž . cantly P -0.001 for each . The time course of drug effects was determined in Group 2 dogs. The effects of dofetilide were stable over time without a maintenance Ž . infusion Fig. 3 , left . The loading and maintenance infusion developed for azimilide was effective in maintaining Ž . drug effects on ERP Fig. 3 , right . The stability of azimilide effects was consistent with the ability of the maintenance infusions to sustain stable plasma concentrations Ž . Table 2 .
The electrophysiologic effects of azimilide and dofetilide at different cycle lengths are detailed in Table 3 . As expected for class III agents, CV was not significantly altered. ERP was increased significantly by both drugs in both the absence and presence of vagal stimulation, with Fig. 4 . Dofetilide's effects showed significant reverse use dependence, in both the absence and presence of vagal stimulation. In contrast, azimilide's actions on ERP were frequency-independent. The second dose of dofetilide produced little additional effect, while the second dose of azimilide had a substantially larger action. Azimilide's effects were less in the presence of vagal nerve stimulation than in its absence.
In order to obtain insights into drug effects on activation during vagal AF, we calculated changes in the AFCL. As shown in Fig. 5 , both drugs increased AFCL. The changes caused by azimilide in AFCL were larger than the changes the drug produced in ERP in the presence of vagal nerve stimulation. In order to analyze these results further, we compared AFCL changes in dogs with and without Ž drug-induced termination based on the seven dogs studied . with each drug in the final protocol . Doses that terminated AF always produced very large increases in AFCL prior to termination, for example, low-dose azimilide increased AFCL by 69 " 20% in dogs in which it terminated AF, compared to 27 " 5% in dogs without termination; lowdose dofetilide increased AFCL by 82 " 22% in dogs with termination compared to 51 " 15% in dogs without termination. High-dose azimilide increased AFCL by 107 " 32% and terminated AF in all dogs who received it. The limited AFCL changes occurring with the higher dose of dofetilide are consistent with its inability to terminate AF in dogs that did not respond to the lower dose.
Discussion
We have found that the investigational antiarrhythmic agent azimilide is effective against AF in an experimental The class III properties of azimilide and dofetilide are qualitatively similar to those of other agents of the same class, such as d-sotalol and ambasilide, that have been w x shown previously to be effective in the same model 14 . Increases in ERP without concomitant decreases in CV result in an increase in the wavelength for reentry, which determines the number of reentry circuits during AF and w x thus the stability of the arrhythmia 12-14,19 . Preliminary reports have been presented which suggest efficacy of w x azimilide in canine atrial flutter 10,11 . In the study of Restivo et al, efficacy was seen in the sterile pericarditis model of atrial flutter with an azimilide dose of 10 mgrkg, but 30 mgrkg was necessary to prevent completely arw x rhythmia reinduction 10 . In the study of Pinto et al. azimilide terminated atrial flutter in dogs with a Y-shaped atrial incision at doses ranging from 2 mgrkg to 11.7 w x mgrkg 11 . While direct comparisons between drug effects on atrial flutter and fibrillation must consider the w x differences in mechanisms between the arrhythmias 19,20 , our observations are consistent with those of the atrial flutter studies in terms of the approximate dose range for azimilide efficacy in canine models of atrial arrhythmia.
The potential ionic mechanisms of azimilide action have been somewhat controversial. Based on early studies w x 3 , azimilide was initially thought to be a highly selective I blocker. Subsequent studies in other laboratories indi- Table 2 . These concentrations are in the range reported to produce 50% and 80% block of I Ks w x respectively 5,6 . Ambasilide, another drug with I Ks w x blocking capability 26 , also produces much less frequency-dependent ERP prolongation compared to d-sotalol w x in the same model 14 . Our findings therefore point towards a significant role for azimilide's I blocking Ks action in its electrophysiological effects in the dog atrium and its efficacy in the AF model we studied. It is noteworthy that significant densities of both I and I have been concentrations achieved were of the order of half the IC 50 for these currents. The lack of azimilide effect on conduc-Ž . tion velocity Table 3 argues against important I blockNa ade. Calcium antagonists are ineffective in terminating w x clinical AF 1 , arguing against a contribution of I Ca inhibition to azimilide's efficacy in canine AF. Electrical remodelling due to AF can be prevented by calcium w x antagonists 29 . While it is unlikely that significant remodelling occurred during the relatively short periods of Ž . AF in the present study F 30 min , a contribution of reduced remodelling cannot be completely excluded.
Several of the observations in the present study are somewhat puzzling. First, while the second dose of dofetilide had larger effects than the first dose, the differences were rather small. If the first dose caused near-maximal I blockade, it would not be surprising if an addiKr tional dose produced a relatively small augmentation in drug effect. This possibility remains speculative without the ability to quantify I inhibition directly in vivo. The Kr ERP-prolonging action of azimilide was substantially smaller in the presence of vagal stimulation compared to Ž . its absence Fig. 3 , in contrast to previous class I and III drugs we have studied, which tend to show larger effects w x in the presence of vagal nerve stimulation 12-14 . The mechanisms underlying this interesting discrepancy, and its potential clinical significance, remain to be determined. rapid rates, such as during AF, it is possible that even with short action potentials I can accumulate and contribute Ks w x significantly to repolarization 2 . These considerations Ž . could explain at least in part the reduced effect of azimilide in the presence of vagal stimulation, as well as its ability to terminate AF despite relatively modest effects on ERP during 1:1 pacing in some cases. These concepts, while potentially interesting and appealing, remain speculative until they can be tested directly.
The present studies have several limitations which must be recognized. First, while the vagal AF model has distinct advantages for the study of mechanisms of drug action on w x AF 31 , and has provided useful insights into the effects Whereas larger doses of azimilide were needed to increase ventricular ERP by 15% at faster rates in the ferret heart, indicating reverse use-dependence, the dose increase w x needed was much larger for dofetilide 32 , consistent with the results of the present study. The blend of inward and outward currents during the action potential plateau, which is known to be species-and tissue-specific may be a crucial determinant of rate-dependent drug effects on APD. Finally, while our results indicate that azimilide alters canine atrial electrophysiology in a fashion different from that of dofetilide, they do not prove that the differences observed are due to I blockade. Previously demonstrated Ks effects on other currents, such as those on I and I , as Ca Na well as effects on membrane currents and ion transport
processes not yet studied, could also conceivably play a role.
Inter-animal variability resulted in some baseline differences between dogs receiving either drug. For example, baseline ERP was shorter in Group 3 dogs receiving Ž . azimilide compared to those receiving dofetilide Table 3 . The opposite was true of Group 2 dogs, among which baseline ERP was longer in those receiving azimilide Ž . compared to those receiving dofetilide Fig. 3 . We cannot exclude a role of baseline differences in contributing to differences in drug responses. On the other hand, relative efficacy rates in terminating AF were similar for Group 2 Ž . dogs dofetilide 33%, azimilide 100% compared to Group Ž . 3 dogs dofetilide 43%, azimilide 100% , despite opposite Ž differences in baseline ERP Group 2: dofetilide -. azimilide; Group 3: azimilide-dofetilide . These observations suggest that differences in baseline ERP are unlikely to account for the efficacy differences between azimilide and dofetilide that we observed.
It has been suggested that the development of I Ks blockers may be an interesting pharmacologic approach to improve antiarrhythmic therapy by virtue of the more desirable rate-dependent profile of action they may possess w x compared to I blockers 2 . Since class III proarrhythmia Kr preferentially occurs at low rates, while AF termination occurs during rapid atrial activation, the reverse use-dependence of I blockers limits efficacy and increases the risk Ks of proarrhythmia, while drugs with preserved effects at Ž . rapid rates like azimilide would be expected to have greater ability to terminate AF with an acceptable risk of proarrhythmia. Azimilide was initially developed because of its potent I blocking actions. Our observations suggest Ks that azimilide does have efficacy in experimental AF, and that its effects on ERP are better preserved at rapid rates than those of the I blocker dofetilide. The clinical signifKr icance of these observations, and the details of underlying ionic mechanisms, remain to be established in future studies.
